Sign In
Buy ELOX
$12.05
+0.300 (+2.55%)
At Close: Jun 26, 2026
Why Eloxx's Stock Is Trading Higher Today
03:14pm, Thursday, 18'th Jun 2020
Eloxx Pharmaceuticals (NASDAQ: ELOX) shares are trading higher on Thursday.The company announced that enrollment in its Phase 2 trial for ELX-02 has resumed in Israel and Europe. It was on pause due t
Price Over Earnings Overview: Eloxx Pharmaceuticals
02:42pm, Thursday, 18'th Jun 2020
Looking into the current session, Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) shares are trading at $3.72, after a 21.97% spike. Moreover, over the past month, the stock spiked by 11.38%, but in the pas
Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by no
Edited Transcript of ELOX earnings conference call or presentation 7-May-20 8:30pm GMT
04:06pm, Thursday, 11'th Jun 2020
Q1 2020 Eloxx Pharmaceuticals Inc Earnings Call
Hedge Funds Are Selling Eloxx Pharmaceuticals, Inc. (ELOX)
04:48pm, Wednesday, 27'th May 2020
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev
U.S. RESEARCH ROUNDUP-Digital Realty Trust, Pilgrims Pride, Terraform Power
07:26am, Tuesday, 12'th May 2020
Wall Street securities analysts revised their ratings and price targets on
several U.S.-listed companies, including Digital Realty Trust, Pilgrims Pride and Terraform Power,
on Tuesday.
HIGH
Eloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q1 2020 Results - Earnings Call Transcript
04:17am, Monday, 11'th May 2020
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Q1 2020 Earnings Conference Call May 7, 2020 16:30 ET Company Participants Barbara Ryan - Investor Relations Greg Will
Eloxx Pharmaceuticals, Inc. (ELOX) Q1 2020 Earnings Call Transcript
07:01pm, Friday, 08'th May 2020
At this time, I would like to turn the call over to Barbara Ryan, Eloxx Investor Relations. Welcome and thank you for joining us this afternoon for a review of Eloxx Pharmaceuticals' first quarter 20
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
11:36am, Friday, 08'th May 2020
Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
Edited Transcript of ELOX earnings conference call or presentation 7-May-20 8:30pm GMT
05:12am, Friday, 08'th May 2020
Q1 2020 Eloxx Pharmaceuticals Inc Earnings Call
Eloxx Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results and Provides Business Update
08:01pm, Thursday, 07'th May 2020
Completing our Phase 2 clinical trial program for ELX-02 in Cystic Fibrosis remains our highest priority Preclinical studies advancing in autosomal dominant polycystic kidney.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Eloxx Pharmaceuticals (OTCMKTS:ELOX) Stock Holdings Increased by Bank of New York Mellon Corp
08:44am, Wednesday, 29'th Apr 2020
Bank of New York Mellon Corp grew its stake in shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) by 7.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange
Eloxx Pharmaceuticals (OTCMKTS:ELOX) Receives Average Recommendation of "Buy" from Analysts
08:40am, Tuesday, 28'th Apr 2020
Shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) have earned a consensus recommendation of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. Two investment analysts
